Prostate Cancer Features Archive
An interview with Neal Shore, MD
Patients diagnosed with prostate cancer often struggle with their diagnosis.
Tumors fall into 1 of 5 grade groups based on what pathologic findings indicate about prognosis.
Additional novel medical therapies to treat prostate cancer and earlier use of the existing medical therapies are the future of prostate cancer management.
Advances in prostate cancer screening, management and therapeutics have vastly improved patient care.
Studies suggest that these cholesterol-lowering drugs can improve treatment of genitourinary cancers and prevent contrast-induced nephropathy.
For decades, prostate cancer risk (PCa) stratification was based primarily on the architectural pattern of the tumor.
Human beings are unique in the animal kingdom when it comes to nutrition.
Rising readmission rates of subsequent sepsis have given urologic surgeon Jeremy Grummet, MBBS, MS, FRACS, pause.
The term "personalized medicine" remains an overused promise to apply specific treatment plans.
Although several biomarkers show promise, PCA3 has garnered substantial attention following FDA approval and its role in the diagnosis of PCa will grow.
Some may find it surprising that Dr. Critz generally considers RP to be the go-to treatment for localized disease.
Innovative approaches offer the potential for effective treatments to limited target areas with improved side effect profiles.
Radium-223 was approved in May 2013 for the treatment of mCRPC with symptomatic bone metastases and no visceral disease.
A nascent technology combines laser optics and ultrasound to distinguish between benign and malignant prostate tissue.
Once again, a study offers evidence that one of the keys to good nutrition is avoiding excess.
While bone loss and reduction in bone mineral density are well known consequences of ADT, the main concern is increased risk of osteoporotic fractures.
Provenge is a breatkthrough treatment option for men with asymptomatic or minimally symptomatic metastatic, hormone-resistant PCa.
Having just returned from the always-stimulating European Association of Urology annual congress, I'd like to share a few impressions.
Ringing in the new year was especially exciting this time around for Ashutosh K. Tewari, MB, BS, head of the new Center for Prostate Cancer at New York-Presbyterian.
It is hoped that selective screening, selective biopsy, and selective therapy will further decrease the morbidity associated with screening.
Considering that bone loss is a known side effect of ADT for men with PCa, it might seem logical that calcium and vitamin D supplementation would help manage this consequence.
The management of patients with high-risk prostate cancer represents one of the biggest challenges today, with little consensus on optimal treatment.
In the past few years, urologists have seen some significant developments related to the treatment of metastatic castration-resistant prostate cancer (CRPC).
Several new drugs have become available for treating advanced prostate cancer in the past year and a half.
More than 1 million prostate biopsies are performed annually in the United States, predominantly driven by elevations in PSA.
Dr. B, 57, was a urologist with a busy private practice. One of his patients was Mr. O, 69, who had an abnormal PSA result.
Having performed more than 1,200 brachytherapy treatments, Michael F. Sarosdy, MD, is convinced that this is a far better choice than surgery.
The March issue features coverage of the 2012 Genitourinary (GU) Cancers Symposium, which was held in San Francisco.
Although HIFU has not yet been approved in the US, a growing number of the nation's urologists are offering this noninvasive surgical procedure.
In determining prostate cancer treatment, physicians should discuss preferences, values, and expectations with patients, including life expectancy, adverse events, and costs
In select patients, use of intermittent therapy does not appear to negatively affect overall survival and is associated with fewer adverse events.
Mani Menon, MD, discusses the place of robotic prostatectomy in the treatment of localized prostate cancer.
A history of prostate cancer has generally been a contraindication for testosterone therapy, but the clinical model may be changing.
This article addresses the issues that must be understood to navigate the scenario posed by patients that have had a prior negative biopsy.
Prostate cancers diagnosed at repeat biopsy are as likely to be high grade as those found at initial biopsy, researchers reported in The Journal of Urology.
Renal and Urology News Articles
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)